Key result
SSRIs are safe post-ischemic stroke but show mixed evidence for neuroprotective efficacy.
Why the study?
New methods to improve motor function recovery after ischemic stroke are needed, and SSRIs have been suggested to have beneficial effects on stroke outcomes.
Do selective serotonin reuptake inhibitors improve neurological and motor function recovery in patients after ischemic stroke?
Do selective serotonin reuptake inhibitors improve neurological and motor function recovery in patients after ischemic stroke?
Current evidence on the neuroprotective effect of SSRIs after ischemic stroke is mixed, highlighting the need for further multicenter studies to confirm efficacy, though their safety is well-established.
Answers are grounded in this paper and cite their sources.
rtPA was associated with improved limb motor strength after ischemic stroke; supports its role but leaves open need for prospective confirmation.
Introduction and purpose:Ischemic stroke accounts for the majority of all stroke cases, with recurrence rates of around 12% within the first year, rising to around 30% within five years.Thrombolytic therapy based on the intravenous administration of rtPA (recombinant plasminogen activator) is the only treatment that has been proven to improve treatment outcomes after ischemic stroke. New methods that would increase the number of motor function returns are still being sought.A brief description of the state of knowledge: SSRIs, selective serotonin reuptake inhibitors are used primarily in the treatment of depression and emotional lability after stroke. Many clinical and preclinical studies have suggested that SSRIs have a beneficial effect on the outcomes of stroke patients.Our work is a brief overview of the current knowledge and clinical trials conducted. Review of the available literature using the PubMed database. Search criteria for scientific articles published from 2010 to 2020, search term: "SSRI ischaemic stroke". Ultimately, 12 randomized clinical trials were analyzed (3 articles apply for one study). One of the studies does not have unequivocal results. Conclusions: The safety of SSRIs in stroke patients has been confirmed. Further multi-center studies are required to investigate the neuroprotective role of SSRIs.
No takes yet. Share an insight, caveat, or question.
Rocka et al. (2020) conducted a review in Ischemic stroke. Selective serotonin reuptake inhibitors (SSRIs) vs. Placebo or standard care was evaluated on Neuroprotective effect and motor function recovery. A review of 12 randomized trials found that while SSRIs are safe for patients after ischemic stroke, evidence for their neuroprotective efficacy is mixed, with 7 studies reporting benefits and 4 finding no positive effects.
Synapse has enriched 10 related papers. Consider them for comparative context: